PharmacoEconomics

, Volume 22, Supplement 3, pp 13–23

Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy

  • Joshua S. Benner
  • Jonothan C. Tierce
  • Christie M. Ballantyne
  • Cheryl Prasad
  • Michael F. Bullano
  • Vincent J. Willey
  • John Erbey
  • David S. Sugano
Original Research Article

Abstract

Introduction and Objective: The National Cholesterol Education Program recommends regular physician follow-up and lipid testing to promote adherence with lipidlowering medications. The objective of this study was to determine whether lipid tests and physician visits after treatment initiation are indeed associated with adherence to statin therapy.

Subjects and Methods: A retrospective cohort study was conducted among 19 422 enrolees in a US managed care plan who initiated treatment with a statin between October 1999 and August 2001. Computerised pharmacy, medical and laboratory records were used to study the patterns and predictors of adherence with lipid-lowering therapy for up to 3 years. Adherence was assessed in 3-month intervals with patients considered ‘adherent’ if ≥80% of days were covered by lipid-lowering therapy.

Results: In the first 3 months, 40% of patients had follow-up lipid tests and only 21% had dyslipidaemia visits (14% had both). Those receiving such care were substantially more likely to be adherent in subsequent intervals. Compared with those without follow-up, the relative odds of adherence were 1.42 and 1.27 for patients with one or more lipid test and one or more dyslipidaemia visit, respectively (95% confidence intervals [CI] 1.33, 1.50 and 1.16, 1.39). Patients who received a followup visit and lipid test were 45% more likely to be adherent (95% CI 1.34, 1.55). Similar associations were observed when lipid tests and dyslipidaemia visits occurred later in therapy.

Conclusion: Early and frequent follow-up by physicians — especially lipid testing — was associated with improved adherence to lipid-lowering therapy. A randomised prospective study is needed to determine whether this relationship is causal.

References

  1. 1.
    The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9Google Scholar
  2. 2.
    Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7PubMedCrossRefGoogle Scholar
  3. 3.
    Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9PubMedCrossRefGoogle Scholar
  4. 4.
    The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57CrossRefGoogle Scholar
  5. 5.
    Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22PubMedCrossRefGoogle Scholar
  6. 6.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7–22CrossRefGoogle Scholar
  7. 7.
    Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–61PubMedCrossRefGoogle Scholar
  8. 8.
    Avorn J, Monette J, Lacour A, et al. Persistence of use of lipidlowering medications: a cross-national study. JAMA 1998; 279: 1458–62PubMedCrossRefGoogle Scholar
  9. 9.
    Sung JCY, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Managed Care 1998; 4: 1421–30Google Scholar
  10. 10.
    Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996; 164: 208–11PubMedGoogle Scholar
  11. 11.
    Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP). Arch Intern Med 2000; 160: 459–67PubMedCrossRefGoogle Scholar
  12. 12.
    The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997; 18: 1718–24CrossRefGoogle Scholar
  13. 13.
    Andrade SE, Saperia GM, Berger ML, et al. Effectiveness of antihyperlipidemic drug management in clinical practice. Clin Ther 1999; 21 (11): 1973–87PubMedCrossRefGoogle Scholar
  14. 14.
    Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002; 113: 625–9PubMedCrossRefGoogle Scholar
  15. 15.
    LaRosa JH, LaRosa JC. Enhancing drug compliance in lipidlowering treatment. Arch Fam Med 2000; 9: 1169–75PubMedCrossRefGoogle Scholar
  16. 16.
    Luepker RV. Patient adherence: a risk factor for cardiovascular disease. Heart Dis Stroke 1993; 2: 418–21PubMedGoogle Scholar
  17. 17.
    Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final version, 2002 [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm [Accessed 2004 Sept 27]
  18. 18.
    Rudd P. Compliance with antihypertensive therapy: a shifting paradigm. Cardiol Rev 1994; 2 (5): 230–40CrossRefGoogle Scholar
  19. 19.
    Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997; 241: 317–25PubMedCrossRefGoogle Scholar
  20. 20.
    Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13–22CrossRefGoogle Scholar
  21. 21.
    Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19 (10): 1434–503Google Scholar
  22. 22.
    Lipids and the primary prevention of coronary heart disease: a national clinical guideline. SIGN publication; no. 40. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN), 1999Google Scholar
  23. 23.
    Secondary prevention of CHD: a national guideline. SIGN publication; no. 41. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN), 2000Google Scholar
  24. 24.
    Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003; 26 Suppl. 1: S83–6PubMedGoogle Scholar
  25. 25.
    AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract 2000; 6 (2): 162–213Google Scholar
  26. 26.
    Shepherd J. Resource management in prevention of coronary heart disease: optimizing prescription of lipid-lowering drugs. Lancet 2002; 359: 2271–3PubMedCrossRefGoogle Scholar
  27. 27.
    Friedman RH, Kazis LE, Jette A, et al. A telecommunications system for monitoring and counseling patients with hypertension: impact on medication adherence and blood pressure control. Am J Hypertens 1996; 9 (4 Pt 1): 285–92PubMedCrossRefGoogle Scholar
  28. 28.
    Logan AG, Milne BJ, Achber C, et al. Work-site treatment of hypertension by specially trained nurses: a controlled trial. Lancet 1979; 2 (8153): 1175–8PubMedCrossRefGoogle Scholar
  29. 29.
    Saunders LD, Irwig LM, Gear JS, et al. A randomized controlled trial of compliance improving strategies in Soweto hypertensives. Med Care 1991; 29 (7): 669–78PubMedCrossRefGoogle Scholar
  30. 30.
    Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976; 1 (7972): 1265–8PubMedCrossRefGoogle Scholar
  31. 31.
    Merenich JA, Lousberg TR, Brennan SH, et al. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). Am J Cardiol 2000; 85 (3A): 36A–42APubMedCrossRefGoogle Scholar
  32. 32.
    De Busk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994; 120(9): 721–9Google Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Joshua S. Benner
    • 1
  • Jonothan C. Tierce
    • 1
  • Christie M. Ballantyne
    • 2
  • Cheryl Prasad
    • 1
  • Michael F. Bullano
    • 3
  • Vincent J. Willey
    • 3
  • John Erbey
    • 4
  • David S. Sugano
    • 4
  1. 1.ValueMedics Research, LLCArlingtonUSA
  2. 2.Baylor College of MedicineHoustonUSA
  3. 3.Health Core, Inc.NewarkUSA
  4. 4.Schering-Plough PharmaceuticalsKenilworthUSA

Personalised recommendations